在合成生物学与精准医疗交织的浪潮下，中国微生态医疗赛道再掀资本狂飙。国内精准菌群移植领域龙头企业承葛生物正式完成新一轮融资，由远翼投资 领投，融资总额过亿元，悟凡资本担任本轮融资顾问。这是继2025年6月完成金阖资本融资后，公司在半年内实现的第二轮重大资本加持。这一重磅融资 不仅刷新行业融资效率的纪录，更释放出强烈的产业信号——人体微生物组的商业化开发已进入爆发前夜。 据Evaluate Pharma预测，到2028年全球微生态药物市场规模将突破超千亿元人民币，而中国作为全球第二大医药市场，增速有望达到全球平均水平的三 倍。承葛生物所在的菌群移植细分领域，更是处于技术突破与应用落地的黄金交叉点。 政策红利：国家卫健委等2023年9月印发的《全国医疗服务项目技术规范（2023年版）》，已将肠道菌群移植纳入医疗服务项目范畴；目前该项目的医保 支付试点已在浙江、广东等地推进。承葛生物主导制定的五项行业标准实施已久，相关政策红利即将全面释放。 超千亿级微生态市场的破局时刻 作为专注医疗健康赛道的头部投资机构，远翼投资此次重仓承葛生物，看中的正是公司构建的多维竞争优势： 承葛生物构建了世界首个精准菌群移植治疗平台（Pr ...

Core Insights - Shanghai Chengge Biotechnology Co., Ltd. has successfully completed a strategic investment round led by Suzhou Jinhui Capital, focusing on the micro-ecological medical field [1][3] - The company has developed the world's first integrated platform for Precision Microbiota Transplantation Therapy (PMTT), which includes a comprehensive solution for deep microbiota analysis, precise matching, standardized preparation, and intelligent delivery [1][3] Company Overview - Chengge Biotechnology, founded in 2016, is a national high-tech enterprise providing comprehensive solutions for precise microbiota transplantation, integrating R&D, manufacturing, sales, and services [3][4] - The company has established itself as a leading player in the industry, with a focus on human micro-ecological transplantation and various related fields, including micro-ecological health, diagnosis, treatment, and data mining [4] Technological Advancements - The PMTT platform includes a "precision screening" sample library, an "intelligent matching" technology platform, and a "standardized production" center that adheres to advanced GMP standards, ensuring safety and efficacy [1][3] - The core product, "liquid live bacteria enteric-coated capsules," has demonstrated significant clinical value [1] Industry Potential - Micro-ecological intervention is viewed as a crucial development direction in future medicine, with Chengge Biotechnology positioned as a pioneer in this field [3] - The company aims to address major clinical needs and promote the industrialization of micro-ecological medicine, benefiting a broader patient population [3]